Combating infectious diseases with reagent banks

Viruses are a small collection of genetic code and powerful pathogens that have caused numerous pandemics of diseases and resulted in millions of deaths as well as economic instability.

When a new viral pathogen emerges, rapid prevention and efficient control solutions are required. Fast-tracked development and supply of premium biological reagents, such as recombinant proteins, antibodies and kits, are crucial for epidemic control and treatment.

Sino Biological (Beijing, China) is well experienced when it comes to the development of such reagents and can deliver high-quality products for researchers to tackle infectious diseases.

A virus is a small parasite that can only replicate inside the living cells of an organism. An independent viron is typically made up of three parts: genetic material, a protein coat and an external envelope of lipids.

Throughout the infection procedure, viruses infect host cells by way of interaction between the virus surface protein (such as spike protein of SARS-CoV-2) and its corresponding receptors (such as ACE2). Once inside, the virus starts to replicate, which is contingent on the host cell’s protein synthesis pathways.

This process will generate a copious amount of genome copies. Then, the viral proteins are synthesized and put together. Finally, the freshly produced viruses are released from the host cells.

Proteins play a crucial role in the virus’ life cycle. Virus structural proteins and enzymes are key tools for evaluating the pathogenesis of viruses, as well as identifying the targets for the development of vaccines, anti-viral drugs, and diagnostic reagents.

With developments in the recombinant protein expression method, it is now possible to create viral proteins in great quantities and utilize them as tools for a range of virological researches.

For recombinant viral structural protein expression, the eukaryote systems are typically chosen because of their appropriate post-translational modifications. These proteins include the spike protein of SARS-CoV-2 (40589-V08H8), fiber protein of ADV (40625-V08B), fusion protein of RSV (11049-V08B), etc.

For nonstructural proteins or nucleocapsid proteins of viruses, the E. coli host is an optimal choice with low-cost and rapid expression. Such products include SARS-CoV-2 N protein (HPLC-40588-V07E), other coronaviruses (40641-V07E), 3C-like protease (40594-V56E), plpro/papain-like protease (40593-V07E), etc.

Anti-virus antibodies are central ingredients in serologic tests, vaccine evaluations and therapy development. To acquire highly sensitive antibodies with high specificity, numerous platforms have been used, including screening of the existed antibodies.

For instance, the spike protein and N protein of SARS-CoV share great similarities in their sequences to those of SARS-CoV-2.

When COVID-19 exploded, Sino Biological was quick off the mark thanks to screening its anti-SARS-CoV antibody library and utilizing the SARS-CoV-2 recombinant proteins to eliminate cross-reactive antibodies and get exceptional sensitive and specific candidates for SARS-CoV-2 (40150-D001 and 40143-MM08).

With years of technical accumulation, Sino Biological has established long-standing multiple recombinant protein expression platforms, such as bacteria, yeast, baculovirus-insect and mammalian expression systems.

With its HEK293-based high-throughput protein/antibody expression platform, hundreds of proteins can be prepared synchronously every week.

It has assembled the world’s largest bank of recombinant viral antigens known as ProVirTM, comprising over 1,000 products from 90+ virus types/subtypes and almost 400 strains, which includes an exclusive SARS-CoV-2 variant antigen bank, a sophisticated influenza vaccine strain antigens collection and numerous hard-to-find viral proteins such as Zika, RSV, Ebola and cytomegalovirus.

Additionally, Sino can provide 400+ antibodies, 3000+ genes and over 900 other reagents for virological research projects and other applications.

The development and manufacture of viral reagent products are in compliance with strict quality control systems (ISO 9001 and ISO 13485). Their advanced properties and biological activity have been established using state-of-the-art detection equipment.

Until now, Sino biological’s viral reagent products have led to over a thousand citations. For SARS-CoV-2 research citations, there are more than 50 articles (and counting) published in Cell, Nature and Science journals.

The central materials for SARS-CoV-2 diagnosis, e.g., 40591-V08H, have been provided to over 200 diagnostic companies around the globe. Sino Biological is ready for new challenges to combat the next infectious diseases in the future.

About Sino Biological Inc.

Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.

Sino Biological's core business

Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and produced. In addition, we offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. Our product quality control indicators meet rigorous requirements for clinical use samples. It takes only a few weeks for us to produce 1 to 30 grams of purified monoclonal antibody from gene sequencing.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Dec 14, 2021 at 2:50 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2021, December 14). Combating infectious diseases with reagent banks. News-Medical. Retrieved on October 07, 2022 from https://www.news-medical.net/whitepaper/20211202/Combating-Infectious-Diseases-with-Reagent-Banks.aspx.

  • MLA

    Sino Biological Inc.. "Combating infectious diseases with reagent banks". News-Medical. 07 October 2022. <https://www.news-medical.net/whitepaper/20211202/Combating-Infectious-Diseases-with-Reagent-Banks.aspx>.

  • Chicago

    Sino Biological Inc.. "Combating infectious diseases with reagent banks". News-Medical. https://www.news-medical.net/whitepaper/20211202/Combating-Infectious-Diseases-with-Reagent-Banks.aspx. (accessed October 07, 2022).

  • Harvard

    Sino Biological Inc.. 2021. Combating infectious diseases with reagent banks. News-Medical, viewed 07 October 2022, https://www.news-medical.net/whitepaper/20211202/Combating-Infectious-Diseases-with-Reagent-Banks.aspx.

Other White Papers by this Supplier